• AC Immune reported week-100 Part 1 Phase 2 VacSYn results for ACI-7104 in early-stage Parkinson’s disease.
• Data were presented now, showing the study met its primary safety, tolerability, and immune-response goals.
• Findings supported antibody activity in the central nervous system, with exploratory signals consistent with target engagement.
• Part 2 design is being finalized to test clinical activity, with FDA discussions on the development path planned for early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230700OMX_____CNEWS_EN_GNW1001274066_en) on September 23, 2026, and is solely responsible for the information contained therein.